Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 12, 2017 01:02 ET | Source: Targovax ASA

Targovax announces one-year survival rate and safety data in the modified cohort of the TG01 trial in resected pancreatic cancer

Oslo, Norway, 11 October 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces...
October 03, 2017 08:49 ET | Source: Targovax ASA

Targovax granted US Patent for mutant-RAS neoantigen platform 2nd generation product TG02

Extends IP protection of TG02 in the US until 09.12.2034 Oslo, 3 October 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology...
September 25, 2017 01:00 ET | Source: Targovax ASA

Targovax granted US Patent for mutant-RAS neoantigen platform lead products

Extends IP protection of TG01 and TG02 until 06.05.2034 Oslo, 25 September 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology...
September 14, 2017 10:01 ET | Source: Targovax ASA

Targovax Receives 2017 Nordic Stars Award

Oslo, Norway, 14 September 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces...
September 12, 2017 09:49 ET | Source: Targovax ASA

Targovax announces start of patient recruitment in phase I/II study with ONCOS-102 in combination with durvalumab in patients with advanced peritoneal malignancies

Oslo, Norway, 12 September 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces start...
September 11, 2017 01:01 ET | Source: Targovax ASA

Targovax ASA: Three posters presented at ESMO conference

Oslo, Norway, 11 September 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today...
August 29, 2017 04:03 ET | Source: Targovax ASA

Targovax ASA: Registration of share capital increase following exercise of employee options and settlement of restricted stock units

Reference is made to the stock exchange notice of 18 August 2017 regarding the board of directors' resolution to increase the share capital in Targovax ASA (the "Company") in connection with the...
August 28, 2017 01:02 ET | Source: Targovax ASA

Targovax ASA: Mandatory notification of trade by primary insider in connection with settlement of RSUs

1. Settlement of vested restricted stock units ("RSUs") Robert Burns, member of the board of directors of Targovax ASA (the "Primary Insider"), has on 25 August 2017 subscribed for 40,984...
August 25, 2017 07:03 ET | Source: Targovax ASA

Exercise of employee share options and restricted stock units in Targovax ASA

Reference is made to the stock exchange notice of 18 August 2017 regarding increase of the share capital in Targovax ASA (the "Company") relating to exercise of employee options and settlement of...
August 24, 2017 01:02 ET | Source: Targovax ASA

Targovax ASA: Second quarter and first half 2017 results

Oslo, Norway, 24 August 2017 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces its second quarter and first...